Zydus Cadila gets USFDA approval to treat tension headache

During the weekend, Zydus Cadila, a part of Cadila Healthcare, informed the bourses that it has received the final approval from United States Food and Drug Administration (USFDA) for Butalbital, Acetaminophen and Caffeine tablets.

The company has received approval to market the above-mentioned medicines in the strengths of 50 mg/325 mg/40 mg. This combination of medicines is used in the treatment of patients suffering from symptoms of tension headaches.

The group has 294 approvals presently and has so far, filed over 390 abbreviated new drug applications (ANDAs) to date, since the commencement of its filing process in FY 2003-04.

Talking about the company’s contribution to COVID-19 treatment, the company is putting all efforts to combat with COVID-19 pandemic. Vaccine Technology Centre (VTC) of Zydus Cadila is capable of developing and manufacturing viral, toxoid, polysaccharide, conjugate, and others. Zydus was the first company in India to develop and indigenously manufacture the vaccine to combat swine flu during the pandemic in 2010.

The company’s revenue mix comprises of US Formulations (49 per cent), India Formulations (28 per cent), EMB Formulations (7 per cent), animal health (6 per cent), Wellness (4 per cent), API (3 per cent), alliances (1 per cent) and Europe Formulations (2 per cent).

Today, the stock of Cadila Healthcare gained nearly two per cent and made an intraday high of Rs 384.70 on BSE.